NICE recommends capivasertib for advanced breast cancer
Clinical trial results revealed that capivasertib, taken with fulvestrant, can provide advanced breast cancer patients with an additional four months before their cancer progresses.
NICE said that capivasertib will be a treatment option for around 1,100 adults with cancer that has recurred or progressed after treatment with a cyclin-dependent kinase 4 and 6 inhibitor plus an aromatase inhibitor
Shutterstock.com
The National Institute for Health and Care Excellence (NICE) has recommended a new combination treatment for locally advanced or metastatic hormone receptor (HR)-positive, HER 2-negative breast cancer for use on the NHS in England and Wales.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
